Key Takeaways SRPT shares fell 35.9% after a third death in its muscular dystrophy gene therapy program from liver failure. FDA placed LGMD studies on hold and urged a halt to Elevidys shipments; SRPT refused, citing safety data. Sarepta will cut 36% of staff and focus on siRNA assets to save $400M annually and stabilize operations.Shares of Sarepta Therapeutics (SRPT) nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies.The company confirmed that a ...

MILWAUKEE, July 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating PharmChem (OTC: PCHM) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcohol Monitoring Systems.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of PharmChem will receive $3.75 per share in cash. PharmChem insiders will recei ...

Welcome back to Squawk on the Street. Healthc care you might know the worst performing sector of the year so far. Just one of just three still in the red since January after we got weakness in one part of the market.The health insurers names like Centine, UNH, Molina, Eleance all have had bad news last couple of weeks. Down double digits on the year and more than cut in half off of their 52- week highs. It's been a non-stop stream of bad news from almost all of those names.Yeah, brutal. Also pharma as well. ...

PHILADELPHIA, July 21, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025, seek to be appointed as a lead plaintiff representa ...

Exelixis (EXEL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 28. On the o ...

Core Insights - Viatris, Inc. (VTRS) announced that its late-stage study on the ophthalmic ointment MR-139 failed to meet primary endpoints in patients with blepharitis, leading to a 4.21% drop in share price [1][6] - Year-to-date, VTRS shares have decreased by 26.8%, contrasting with a 9% decline in the industry [1] Study Details - The MR-139 study was a randomized, placebo-controlled, double-masked phase III trial involving approximately 477 patients, who self-administered the treatment twice daily for 12 weeks [3] - The primary endpoint of complete resolution of eyelid debris after six weeks was not achieved [3][6] Future Plans - VTRS is evaluating next steps for the MR-139 phase III program, which may involve revising the planned additional study [4][6] - The company is focusing on its ophthalmology portfolio, which includes therapies like Tyrvaya and Ryzumvi, and aims to address unmet needs in anterior segment conditions [4] Portfolio Strengthening - VTRS has established an ophthalmology franchise through acquisitions of Oyster Point Pharma and FamyLife Sciences [6] - The company is restructuring its business following the sale of its biosimilar portfolio and divesting its over-the-counter and Active Pharmaceutical Ingredients businesses in India, as well as its women's healthcare segment, to streamline core operations [7]

An updated edition of the June 10, 2025, article.The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025.Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generatio ...

Key Takeaways JNJ beat Q2 estimates and raised full-year guidance on strong pharma performance. Innovative Medicine sales rose despite Stelara LOE, aided by key drugs and new launches. MedTech improvement was led by cardiovascular and surgical products, which offset China-related headwinds.Johnson & Johnson (JNJ) delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product, Stelara, J&J’s ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, helping investors select stocks with high potential for market outperformance [3] Zacks Style Scores Overview - The Zacks Style Scores categorize stocks based on value, growth, and momentum characteristics, assigning ratings from A to F [4] - Value Score focuses on identifying undervalued stocks using financial ratios [4] - Growth Score evaluates a company's financial health and future growth potential [5] - Momentum Score identifies optimal times to invest based on price trends and earnings estimates [6] - VGM Score combines all three styles, providing a comprehensive rating for stocks [7] Zacks Rank and Style Scores Interaction - The Zacks Rank utilizes earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988 [8] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for optimal returns [10] Company Spotlight: Array Technologies, Inc. - Array Technologies, Inc. is a biopharmaceutical company focused on targeted small molecule drugs for cancer treatment [12] - The company has a marketed therapy, Braftovi plus Mektovi, approved for specific melanoma cases [12] - Array Technologies holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong investment potential [13] - The company has a forward P/E ratio of 10.83, appealing to value investors [13] - Recent upward revisions in earnings estimates suggest positive momentum, with a consensus estimate of $0.66 per share for fiscal 2025 [13] - With solid rankings and scores, Array Technologies is recommended for investors [14]

July 18, 2025 02:21 PM GMT Biopharma | North America A picture is worth a thousand words Comprehensive US drug market analysis (IQVIA Rx). The latest weekly Total Prescription YoY growth (wk ending 7/11) was +4.0% vs. +3.4% last wk and +2.5% over the past 12 wks. For week ended Jul 11, US total market weekly TRx YoY change was +4.0% vs. +1.8% year ago ( Exhibit7 ). Rolling 4-week TRx YoY was +3.0% and rolling 12-week TRx YoY was +2.5%. Extended unit (EUTRx) weekly YoY growth was +3.3%, below TRx YoY ( Exhib ...